Market Place
Sourcing Support
Patients with hidradenitis suppurativa experienced efficacy with Cosentyx
03 Feb 2023 //
GLOBENEWSWIRE
Novartis ties HQ raid to Cosentyx patent fight against Lilly
26 Oct 2022 //
FIERCEPHARMA
Novartis Cosentyx shows improvements with hidradenitis suppurativa
09 Sep 2022 //
GLOBENEWSWIRE
EU approves Norvatis’ Cosentyx for childhood arthritis
30 Jun 2022 //
PHARMATIMES
Novartis Cosentyx nabs +ve CHMP opinion for expanded use in childhood arthritis
20 May 2022 //
GLOBENEWSWIRE
Acelyrin snags $250M, licenses Affibody IL-17 asset for 3 trials
16 Nov 2021 //
FIERCEBIOTECH
Cosentyx displays a 72 percent reduced arthritis flare risk
10 Nov 2021 //
EUROPEANPHARMACEUTICALREVIEW
Novartis’ Cosentyx cuts flare risk in juvenile idiopathic arthritis trial
09 Nov 2021 //
CLINICALTRIALSARENA
Key players in psoriasis offer strong support through branded digital channels
13 Sep 2021 //
BIOSPECTRUM ASIA
NICE recommends Novartis’ Cosentyx for children with severe psoriasis
03 Sep 2021 //
PHARMATIMES
NICE approves secukinumab for young people with severe plaque psoriasis
03 Sep 2021 //
PHARMA FILE
Kevin Judice plays DiCE, pivoting from a $60M raise
27 Aug 2021 //
ENDPTS
China NMPA approves Novartis’ Cosentyx in pediatric patients
19 Aug 2021 //
PHARMABIZ
Cosentyx wins NICE backing for non-radiographic axial spondyloarthritis
17 Jun 2021 //
PHARMATIMES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.